Independent U.S. Market Research

Biotech Catalysts, Stock Hubs & U.S. Small/Mid-Cap Research

Merlintrader publishes independent educational research on U.S.-listed biotech and small- and mid-cap stocks, with daily market briefings, FDA and PDUFA tracking, catalyst calendars and dedicated company hubs across biotech, space, defense, AI, cannabis, energy and critical minerals.

Merlintrader’s Daily Briefing

Monday, August 3, 2026, evening edition. The prices below are intraday, taken around 2:00 p.m. New York time with the US session still open, and are flagged as such throughout. One decision set the tone: President Trump called off a planned strike on Iran to pursue a deal on reopening the Strait of Hormuz, and the war premium came out of crude in a single move. Oil fell about 5% below $80 a barrel, the 10-year Treasury yield dropped 6 basis points to 4.684%, and equities rallied broadly with AI and cloud names in front. The July ISM manufacturing survey printed 55.6, the strongest reading since May 2022. Palantir reports after the close; Friday’s payrolls report is still the week’s real test.

Iran and the risk unwind
  • Iran — President Trump suspended a planned military strike and said fresh negotiations with Tehran would begin, telling reporters that regional allies including Saudi Arabia had urged Washington to pursue diplomacy. Iran denied direct talks with the United States while saying discussions with Oman were making progress on shipping through the strait.Geopolitics
  • Crude — US benchmark crude fell about 5% to below $80 a barrel. The oil tracker $USO traded at $121.36, down 6.05%, and the energy sector fund $XLE at $58.81, down 1.25% — the only major group in the red on a broadly higher tape.Energy
  • Treasuries — The 10-year note yield fell 6 basis points to 4.684% as the energy shock unwound. The long-bond fund $TLT was flat at $82.22, so the move was concentrated in the belly of the curve rather than the very long end.Bonds
  • Yen — The weekend confirmation that Tokyo and Washington acted jointly on the currency — the first coordinated yen-buying operation since 2011 — remains the second live macro variable, because Japanese portfolio flows are a material buyer of the US long end.FX
US session, intraday
  • Indexes — Around 2:00 p.m. ET the S&P 500 tracker $SPY stood at $758.07, up 1.48%; the Nasdaq-100 tracker $QQQ at $701.01, up 1.89%; the Dow tracker $DIA at $530.48, up 1.17%; and the small-cap tracker $IWM at $296.05, up 1.67%. These are intraday levels, not closing prints.Wall Street
  • ISM manufacturing — The July Manufacturing PMI registered 55.6%, against a 54.0% consensus and 53.3% in June, the highest reading since May 2022. New orders were 56.7%, production jumped to 58.5% from 52.2%, and employment returned to expansion at 52.8% for the first time in nearly three years.Macro
  • Megacaps — $AMZN traded at $283.73, up 4.47%, extending Friday’s cloud-driven move, while $AAPL was at $306.09, down 0.91%, still carrying its guidance problem. $NVDA stood at $208.29, up 3.76%.Big Tech
  • Semis — $AMD was at $488.98, up 2.69%, ahead of its own results on Tuesday, and $MU at $834.06, up 1.34%. The semiconductor fund $SMH traded at $547.30, up 1.25%, lagging the Nasdaq on the day.Semis
Healthcare and biotech
  • $AZN $BMY — AstraZeneca traded at $156.95, down 7.48%, after the Financial Times and Bloomberg reported early-stage merger discussions with Bristol Myers Squibb that would create a group worth roughly $400 billion. Bristol Myers was at $65.00, down 0.48%, having been higher premarket. Neither company confirmed the report, and analysts quoted by CNBC described themselves as perplexed by the industrial logic.M&A
  • $REPL — The FDA target action date for RP1 with nivolumab was Sunday, August 2. As of this update no agency decision and no company announcement had been published. The shares traded at $11.72, up 4.68%, after the advisory committee voted 10–3 on July 30 that the IGNYTE efficacy results are evaluable and clinically meaningful.FDA
  • $MRNA — Moderna traded at $56.15, up 2.43%, with an FDA target action date of August 5 for the seasonal influenza vaccine mRNA-1010, which would be its fifth approved commercial product.PDUFA
  • $XBI — The biotech fund was at $147.06, essentially unchanged at plus 0.03%, against a broad market up more than 1%. The sector did not participate in the risk-on move.Sector
AI, cloud and data centre
  • $CRWV — CoreWeave was the standout at $83.83, up 16.81% on about 28 million shares, as the geopolitical relief flipped AI cloud names higher and Wolfe Research reiterated an Outperform rating with a $150 price target. The company reports on August 11.AI cloud
  • $PLTR — Palantir traded at $125.72, up 2.16%, into second-quarter results after the close. Company guidance was $1.797–1.801 billion in revenue against a consensus near $1.81 billion, about 81% annual growth, with full-year guidance of $7.650–7.662 billion. After the first-quarter report the shares fell despite a beat, so the reaction function matters more than the print.Earnings
  • Small-cap AI — $ONDS traded at $8.31, up 10.99% on about 37 million shares, $POET at $7.38, up 5.51%, $PDYN at $5.59, up 6.98%, $BBAI at $2.88, up 3.23%, and $SOUN at $6.16, up 0.49%.Watchlist
Space, defence and nuclear
  • Space — $ASTS traded at $64.42, up 9.22%, with a Falcon 9 launch scheduled for August 5; $RKLB at $69.68, up 7.28%; $LUNR at $13.09, up 6.04%; $PL at $21.50, up 4.96%; and $SPCE at $2.80, up 9.80%.Sector
  • Defence — $AVAV traded at $157.07, up 5.16%, and $UMAC at $22.87, up 8.08%. Note the direction: defence names rose on the same session in which the war premium came out of oil, which says the bid is programme-driven rather than headline-driven.Sector
  • Nuclear and uranium — $OKLO traded at $41.94, up 8.00%, $LEU at $186.13, up 5.20%, $CCJ at $89.23, up 3.30%, and $UEC at $9.96, up 3.75%. The nuclear complex tracked the AI power theme rather than the oil move.Energy
Merlintrader watchlist, intraday
  • Biotech — $SLS traded at $10.99, up 9.79% on about 3.8 million shares, $AGIO at $30.79, up 2.56%, $CAPR at $3.96, up 2.99%, $VERA at $31.97, down 0.40%, $GERN at $1.26, down 1.94%, and $ETON at $45.10, down 2.84%.Small cap
  • Other — $TLRY traded at $4.73, up 4.08%, and $REGN at $763.60, up 0.13%. $VKTX was at $32.49, up 2.36%.Watchlist
Ahead
  • Tonight — Palantir’s second-quarter results and call after the close are the session’s last event, and the after-hours reaction will set the tone for the AI complex on Tuesday.Aug 3
  • Tuesday — Trade balance at 8:30 a.m. ET and JOLTS at 10:00 a.m., with AMD reporting after the close.Aug 4
  • Rest of week — ISM services on Wednesday, weekly claims and productivity on Thursday, and the July employment report on Friday at 8:30 a.m. ET, where a Reuters survey points to about 83,000 jobs added and 4.3% unemployment.Aug 5–7
  • What is not confirmed — Two items in this update are open rather than settled: no FDA decision on RP1 had been published at the time of writing, and European closing levels could not be verified from a primary source, so none are quoted here. The US prices are intraday, not closes.Transparency
Read the full Daily BriefingRead the Weekly Market Pulse

Biotech Catalyst Calendar 2026

Last updated: 22 July 2026

Merlintrader tracks upcoming biotech catalysts for U.S.-listed companies, including PDUFA dates, FDA decisions, clinical-trial readouts, advisory committee meetings and other regulatory milestones. Alongside each date you will find the source, company context and the key risks that can move the stock, plus links to deeper Merlintrader research when it is available. The focus is educational and risk-aware, with particular attention to small and mid-cap biotech names, where catalyst timing, cash runway and dilution risk can drive sharp moves in volatility. Dates can change and FDA decisions can arrive early or late, so always confirm an event against company filings and regulatory sources before acting on it.

Listed / exchange-traded biotech focus

Weekly Biotech Catalyst Tracker

Window covered: July 31 → September 30, 2026. Compact homepage board for unresolved FDA decisions, regulatory submissions and major clinical readouts. A prior-date item remains visible only when the regulatory outcome has not yet been publicly disclosed. October and later events are excluded from this widget.

35Active
17FDA / Reg
18Data / Filing
Jul 31Updated
FDA / PDUFA Clinical data Filing watch High risk Large cap
$NRXPKETAFREEJul 29*PendingGDUFA goal passed; public FDA outcome pending

NRx Pharmaceuticals. The FDA-assigned July 29 GDUFA goal date for the KETAFREE preservative-free IV ketamine ANDA has passed. As of the July 31 update, no approval, tentative approval or complete response had been publicly disclosed by the company, so the item remains active as an unresolved regulatory watch. This is an ANDA event, not a PDUFA for NRX-100 or NRX-101.

$REPLRP1Aug 2PDUFAMelanoma BLA resubmission

Replimune. BLA resubmission goal date for RP1. This is a very compressed AdCom-to-PDUFA setup with elevated regulatory risk.

$MRNAmFLUSIVAAug 5PDUFAmRNA seasonal flu

Moderna. Following the FDA advisory committee’s unanimous June endorsement, the BLA PDUFA for the mRNA seasonal flu vaccine candidate in adults 50+ is due August 5. Approval remains pending; the event is more of a platform and lifecycle read-through than a pure small-cap binary.

$REGNgaretosmabAugFDAFOP ultra-rare disease

Regeneron. BLA target action month for garetosmab in adult fibrodysplasia ossificans progressiva. Month-only calendar item.

$LNTHMK-6240Aug 13NDATau PET imaging

Lantheus. NDA PDUFA for MK-6240 tau PET imaging in Alzheimer’s disease. Diagnostic/imaging catalyst, not a therapeutic efficacy binary.

$CAPRderamiocelAug 22Extreme riskPDUFA after 9–3 negative efficacy vote

Capricor. The BLA remains under FDA review for the treatment of DMD cardiomyopathy, but the July 29 advisory committee voted 9–3 that the available evidence did not provide substantial evidence of effectiveness. FDA is not legally bound by the vote, yet the combination of the negative panel recommendation, disputed endpoint analyses and prior CRL history makes the August 22 decision an extreme-risk regulatory event.

$RAREDTX401Aug 23BLAGSDIa gene therapy

Ultragenyx. Priority Review BLA PDUFA for DTX401 in glycogen storage disease type Ia. First of two near-term Ultragenyx gene-therapy decisions.

$BIIBLeqembi IQLIKAug 24sBLASC starting dose

Biogen / Eisai. sBLA PDUFA for once-weekly subcutaneous Leqembi starting-dose use. Large-cap Alzheimer’s lifecycle catalyst.

$JAZZZiihera comboAug 25sBLA1L HER2+ GEA

Jazz Pharmaceuticals. sBLA PDUFA for Ziihera combination use in first-line HER2-positive gastroesophageal adenocarcinoma.

$GILDBIC/LENAug 27NDAOnce-daily HIV regimen

Gilead. NDA PDUFA for bictegravir/lenacapavir in virologically suppressed adults. Strategic HIV franchise catalyst.

$PTGXrusfertideQ3PDUFAPolycythemia vera

Protagonist / Takeda. Priority Review NDA window for rusfertide in polycythemia vera. Exact date not pinned in this compact board.

$GSKzidesamtinibSep 18NDAROS1+ NSCLC · acquired Nuvalent asset

GSK / former Nuvalent. GSK completed its acquisition of Nuvalent on July 15 and $NUVL ceased trading. The September 18 FDA PDUFA for zidesamtinib in TKI-pretreated ROS1-positive non-small-cell lung cancer remains active, but it is now a large-cap $GSK regulatory catalyst rather than an $NUVL trading event.

$RAREUX111Sep 19RiskSanfilippo A gene therapy

Ultragenyx. Resubmitted BLA PDUFA for UX111 in Sanfilippo syndrome type A. CMC and facility risk remain the key swing factors.

$IONSzilganersenSep 22NDAAlexander disease

Ionis. NDA PDUFA for zilganersen in Alexander disease. Rare neurological disease Priority Review event.

$BFRIAmeluz PDTSep 28sNDASuperficial BCC expansion

Biofrontera. PDUFA for Ameluz photodynamic therapy sNDA seeking expansion into superficial basal cell carcinoma. Small-cap liquidity can amplify reaction.

$SRRKapitegromabSep 30BLASpinal muscular atrophy

Scholar Rock. BLA PDUFA for apitegromab in spinal muscular atrophy. Manufacturing and fill-finish facility status remain key watch items.

$ROIVbrepocitinibQ3NDADermatomyositis

Priovant / Roivant. NDA Priority Review window for brepocitinib in dermatomyositis. Company has pointed to potential launch timing by end-September if approved.

$QUREAMT-130Q3BLAHuntington’s AA path

uniQure. Planned BLA submission for AMT-130 in Huntington’s disease. Not a PDUFA, but one of the most important regulatory-pathway events in the quarter.

$SLNdivesiranAugDataSANRECO Phase 2 PV

Silence Therapeutics. SANRECO Phase 2 topline data for divesiran in polycythemia vera. Important read-through alongside $PTGX / Takeda rusfertide.

$IMMXNXC-201Q3DataAL amyloidosis

Immix Biopharma. NEXICART-2 topline data for NXC-201 in relapsed/refractory AL amyloidosis. BLA-enabling study, high-volatility small-cap setup.

$KPTIselinexorNearDataEndometrial cancer Ph3

Karyopharm. XPORT-EC-042 Phase 3 topline data for selinexor in endometrial cancer. Treat as near-term until released or formally delayed.

$KODDAYBREAKQ3DataWet AMD Phase 3

Kodiak Sciences. DAYBREAK Phase 3 topline data for tarcocimab / KSI-501 in wet AMD. Watch efficacy, durability, dosing interval and safety.

$ALMSenvudeucitinibQ3DataSLE Phase 2b

Alumis. LUMUS Phase 2b readout for envudeucitinib in systemic lupus erythematosus. Autoimmune data can be noisy; dose response matters.

$IVVDVYD2311Q3DataDECLARATION pivotal

Invivyd. DECLARATION pivotal / Phase 3 topline data for VYD2311. COVID-antibody sentiment can be unstable, but pivotal data can still move the name.

$MPLTML-007C-MAMid-AugDataZEPHYR schizophrenia Ph2

MapLight Therapeutics. Phase 2 ZEPHYR topline results for ML-007C-MA in schizophrenia. CNS readout with potentially sharp binary reaction.

$AMLXavexitideQ3Ph3PBH pivotal LUCIDITY

Amylyx. Phase 3 LUCIDITY topline results for avexitide in post-bariatric hypoglycemia. One of the clearest Phase 3 clinical binaries of the quarter.

$PHVSdeucrictibant ERQ3Ph3HAE prophylaxis Ph3

Pharvaris. Phase 3 CHAPTER-3 data for extended-release deucrictibant as prophylaxis for hereditary angioedema. Major HAE readout.

$SYRESPY003Q3DataIBD / UC Phase 2

Spyre Therapeutics. Phase 2 SKYLINE Part A topline data for SPY003 in inflammatory bowel disease and ulcerative colitis.

$VERATrutakna / ataciceptQ3eGFRORIGIN 3 follow-up

Vera Therapeutics. ORIGIN 3 eGFR analysis following accelerated approval. Not another approval decision, but important for durability and confirmatory confidence.

$OCGNOCU410STQ3DataStargardt interim analysis

Ocugen. Interim OCU410ST analysis after 24 patients complete eight months of follow-up in Stargardt disease. Small-cap ophthalmology catalyst.

$XENEazetukalnerQ3NDAFocal-onset seizures filing

Xenon. Expected NDA submission for azetukalner in focal-onset seizures. Filing confirmation would set up future FDA acceptance and PDUFA timing.

$BBIOinfigratinibQ3NDAAchondroplasia filing

BridgeBio. Expected NDA submission for infigratinib in achondroplasia. Submission timing and acceptance will define the next regulatory leg.

$CLNNCNM-Au8Q3NDAALS accelerated pathway

Clene. Targeted NDA submission for CNM-Au8 in ALS through an accelerated pathway. Very high regulatory strategy risk because submission does not guarantee acceptance.

$OCGNOCU400Q3BLARolling BLA start

Ocugen. Expected start of rolling BLA submission for OCU400 in retinitis pigmentosa. Filing progress, manufacturing and future acceptance are the next watch items.

$MLTXsonelokimabLate SepBLAHS filing watch

MoonLake. Planned BLA submission for sonelokimab in hidradenitis suppurativa around the end of September. Acceptance would create the next formal FDA calendar item.

Most attention-worthy watchlist

$NRXP$REPL$CAPR$RARE$GSK$IONS$SRRK$AMLX$PHVS$QURE

Board rule

Only unresolved catalysts through September are shown. Past events are removed once an outcome is publicly confirmed; a passed target date may remain visible when the FDA action has not yet been disclosed. $NRXP therefore remains marked Pending after its July 29 KETAFREE GDUFA goal date. October and later events are intentionally excluded. $NUVL was acquired by GSK and ceased trading, so the September zidesamtinib catalyst is shown under $GSK. Events carrying only Q3 guidance must be rechecked against company filings before trading around them.

Educational content only — not investment advice. Verify dates and filings before trading around binary events.Full catalyst calendarFDASEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.